Johnson & Johnson (JNJ)

JNJ (NYSE:Drugs) EQUITY
$125.79
pos +0.31
+0.25%
Today's Range: 125.15 - 126.14 | JNJ Avg Daily Volume: 7,124,800
Last Update: 03/27/17 - 3:59 PM EDT
Volume: 4,999,939
YTD Performance: 8.91%
Open: $125.16
Previous Close: $125.48
52 Week Range: $107.69 - $129.00
Oustanding Shares: 2,710,891,992
Market Cap: 341,301,301,793
6-Month Chart
TheStreet Ratings Grade for JNJ
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 6 6 7 8
Moderate Buy 2 2 2 2
Hold 10 10 9 8
Moderate Sell 0 0 0 0
Strong Sell 0 1 1 1
Mean Rec. 2.22 2.37 2.26 2.16
Latest Dividend: 0.80
Latest Dividend Yield: 2.54%
Dividend Ex-Date: 02/24/17
Price Earnings Ratio: 21.23
Price Earnings Comparisons:
JNJ Sector Avg. S&P 500
21.23 21.20 30.30
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
8.21% 15.85% 31.81%
GROWTH 12 Mo 3 Yr CAGR
Revenue 2.60 0.00 0.00
Net Income 7.30 0.20 0.06
EPS 8.20 0.20 0.07
Earnings for JNJ:
EBITDA 24.92B
Revenue 71.89B
Average Earnings Estimates
Qtr (03/17) Qtr (06/17) FY (12/17) FY (12/18)
Average Estimate $1.76 $1.79 $7.01 $7.44
Number of Analysts 9 8 10 11
High Estimate $1.80 $1.83 $7.07 $7.80
Low Estimate $1.71 $1.67 $6.95 $7.22
Prior Year $1.68 $1.74 $6.73 $7.01
Growth Rate (Year over Year) 4.83% 2.73% 4.18% 6.12%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
RMPIA
By

Ed Ponsi

 | Mar 23, 2017 | 10:00 AM EDT
If opportunity knocks, I'm buying.
RMPIA
By

Doug Kass

 | Mar 15, 2017 | 5:23 PM EDT
"I had nothing to offer anybody except my own confusion." -- Jack Kerouac 
RMPIA
By

Doug Kass

 | Mar 13, 2017 | 12:47 PM EDT
Healthcare stocks had a heckuva four-year period of over-performance that ended in the summer of 2015. Since then the Health Care Select Sector SPDR ETF (XLV) (40% pharma and 15% biotech) has had a series of trading-range moves as sector prices lagged. Last year more than $18 billion was redeemed out of the healthcare ETFs, according to Morningstar. However there are some technical signposts that the two-year period of underperformance might be ending, as a basing seems likely. Look at the chart and note the recent higher high.
RMPIA
By

Jim Cramer

 | Mar 6, 2017 | 6:50 AM EST
Bull market number one, perhaps of all time: the financials.
By

Jim Cramer

 | Feb 28, 2017 | 11:30 AM EST
Let's recognize that some moves are simply related to bonds, which are in the grips of a bizarre developed-world shortage.
RMPIA
By

Jim Cramer

 | Feb 27, 2017 | 12:27 PM EST
There are nearly too many surging sectors to count.
By

Jim Cramer

 | Feb 24, 2017 | 12:09 PM EST
It's better to be early than wrong. Though being wrong isn't so awful.
RMPIA
By

Jim Cramer

 | Feb 22, 2017 | 11:45 AM EST
Icahn may have a tough time finding interest in this behemoth.
RMPIA
By

Doug Kass

 | Feb 21, 2017 | 2:55 PM EST
 
RMPIA
By

Bruce Kamich

 | Feb 16, 2017 | 11:18 AM EST
You might want to review your holdings in the sector.
Shares of Coach appear to be back in rally mode today. The stock is up over 2.25%(Ka...

REAL MONEY PRO'S BEST IDEAS

News Breaks

Powered by
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.